Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

184
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
184
Pneumonia IV: Management01:28

Pneumonia IV: Management

304
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
304
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

224
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
224
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

239
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
239

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiological factors associated with the recurrence of <i>Mycobacterium avium complex</i> pulmonary disease: a multicentre retrospective cohort study.

Thorax·2026
Same author

Inhibition of SRC prevents bone metastasis of breast cancer by blocking metastatic cell motility and bone directionality.

Theranostics·2026
Same author

Prognostic Value of the Eosinophil-to-Neutrophil Ratio for In-Hospital Mortality in Patients Hospitalized with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Chonnam medical journal·2026
Same author

ADAMTS4 elicits myeloid-derived immune cell recruitment and liver fibrogenesis in metabolic dysfunction-associated steatotic liver disease.

Signal transduction and targeted therapy·2026
Same author

Impact of vitamin D deficiency on 6-month culture conversion in nontuberculous mycobacterial pulmonary disease.

Scientific reports·2026
Same author

Factors associated with extended treatment duration in patients with drug-susceptible pulmonary tuberculosis: a prospective multicentre cohort study in South Korea.

BMC infectious diseases·2026

Related Experiment Video

Updated: Jun 11, 2025

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD &#8212; A Safe, Cost-Effective Approach
04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

709

Corticosteroid Therapy Duration and Dosage According to the Timing of Treatment Initiation for Post-COVID-19

Chang-Seok Yoon1, Hwa-Kyung Park1, Jae-Kyeong Lee1

  • 1Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.

Chonnam Medical Journal
|October 9, 2024
PubMed
Summary
This summary is machine-generated.

Early steroid treatment for organizing pneumonia after COVID-19 may reduce treatment duration and dosage. This study analyzed 91 patients, finding earlier intervention linked to better outcomes in post-COVID-19 pulmonary complications.

Keywords:
Corticosteroid TherapyEarly Therapeutic InitiationPost-COVID-19 Organizing Pneumonia

More Related Videos

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
13:27

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

48.0K
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

605

Related Experiment Videos

Last Updated: Jun 11, 2025

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD &#8212; A Safe, Cost-Effective Approach
04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

709
Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
13:27

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

48.0K
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

605

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • COVID-19 frequently causes pulmonary complications, including organizing pneumonia.
  • Steroids are crucial for treating post-COVID-19 organizing pneumonia.
  • Limited research exists on the benefits of early steroid initiation for this condition.

Purpose of the Study:

  • To investigate the association between the timing of steroid initiation and treatment duration and dosage in patients with post-COVID-19 organizing pneumonia.

Main Methods:

  • Retrospective analysis of 91 patients diagnosed with post-COVID-19 organizing pneumonia.
  • Patients were categorized into early (<18.4 days post-COVID-19) and late (≥18.4 days post-COVID-19) steroid treatment groups.
  • Comparison of steroid treatment duration and dosage between the two groups.

Main Results:

  • The early treatment group (n=55) had a mean steroid duration of 43.1±18.3 days and dosage of 0.5±0.3 mg/kg/day.
  • The late treatment group (n=36) had a longer mean duration of 59.1±22.6 days and higher dosage of 0.8±0.3 mg/kg/day (p<0.01 for both).
  • Steroid initiation time significantly influenced treatment duration (β=0.80, p<0.01) and dosage (β=0.03, p<0.01).

Conclusions:

  • Early steroid initiation for post-COVID-19 organizing pneumonia is associated with shorter treatment duration.
  • Earlier treatment also correlates with lower corticosteroid dosage requirements.
  • These findings suggest potential clinical benefits of timely steroid therapy in managing post-COVID-19 pulmonary complications.